Elaprase 2mg/ml (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 19 | Lysosomal storage disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006044-22-PL (EUCTR) | 21/04/2008 | A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy - not available | A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy - not available | Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome) MedDRA version: 10.1;Level: PT;Classification code 10056889;Term: | Trade Name: Elaprase 2mg/ml Product Name: Idursulfase (I2S) Product Code: I2S INN or Proposed INN: Idursulfase Other descriptive name: Idursulfase | Shire Human Genetic Therapies, Inc. (Shire HGT) | NULL | Not Recruiting | Female: no Male: yes | 30 | Phase 4 | Poland |